https://www.oncologynurseadvisor.com Thu, 04 Jan 2024 20:09:34 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/gynecologic-cancer/esmo-2023-gynecologic-cancer-studies-may-change-practice/ Tue, 07 Nov 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=113874 Phase 3 studies presented at the ESMO Congress 2023 may change the way gynecologic cancers are treated, according to researchers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/updated-acs-guidelines-recommend-screening-more-patients-for-lung-cancer/ Thu, 02 Nov 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=113869 The American Cancer Society has updated its guidelines for lung cancer screening to expand the population of patients who should be screened.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/gut-microbiome-may-aid-diagnosis-prognostication-in-metastatic-nsclc/ Fri, 15 Sep 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=110565 Researchers have found evidence to suggest that patients with metastatic non-small cell lung cancer have unique gut microbiomes. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/global-incidence-of-early-onset-cancers-rose-80-from-1990-to-2019-2/ Thu, 14 Sep 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=110467 New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/neoadjuvant-camrelizumab-combos-demonstrate-efficacy-in-stage-ii-iii-nsclc/ Thu, 14 Sep 2023 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=110502 Neoadjuvant camrelizumab in combination with either platinum-doublet chemotherapy or apatinib has demonstrated efficacy in stage II-III NSCLC, according to researchers. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/car-t-cell-therapy-ari0002h-produces-responses-in-relapsed-refractory-mm/ Fri, 14 Jul 2023 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=109077 The CAR T-cell therapy ARI0002h can produce durable responses in patients with relapsed or refractory multiple myeloma, a pilot study suggests.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/perioperative-nivolumab-improves-outcomes-in-stage-iiia-b-nsclc/ Thu, 13 Jul 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=109079 Adding perioperative nivolumab to neoadjuvant chemotherapy improves outcomes in patients with resectable stage IIIA-B NSCLC, a phase 2 trial suggests.]]> https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/niraparib-improves-rpfs-in-patients-with-mcrpc-and-hrr-alterations-2/ Wed, 12 Jul 2023 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=109149 Adding niraparib to first-line treatment with AAP can improve outcomes in patients with mCRPC and HRR alterations, a phase 3 trial suggests.]]> https://www.oncologynurseadvisor.com/reports/neoadjuvant-folfirinox-resectable-pancreatic-cancer-does-not-improve-os/ Mon, 05 Jun 2023 14:50:00 +0000 https://www.oncologynurseadvisor.com/?p=108148 Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/hiv-cancer-drug-drug-interactions-risk/ Fri, 21 Apr 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=106775 As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers. ]]>